CBD /

 

Loading...
Country's Decision or any other Communication (DEC)
  |  
BCH-DEC-BR-109751-1   |   PDF   |   Print   |  
| 
|  Close
last updated: 27 Feb 2014
Amendment
No
General Information
Brazil
Commercial Release of Live lyophilized vaccine against Fowl Pox and Mycoplasma gallisepticum - VECTORMUNE® FP MG
EN
27 Feb 2009
No
Subject of the decision, notification, communication or declaration
  • Decision on Pharmaceuticals (Article 5)
LMO identification & risk assessment
  • BCH-LMO-SCBD-105419-1 Living Modified Organism VECTORMUNE® FP MG Vaccine
    Ceva Saúde Animal Ltda(CEVA) | Production of medical or pharmaceutical compounds (human or animal) (Vaccines)
  • BCH-RA-BR-109750-1 Risk Assessment generated by a regulatory process Risk assessment of  Live lyophilized vaccine against Fowl Pox and Mycoplasma gallisepticum - VECTORMUNE® FP MG
Document on the decision, communication, notification or declaration

Quick links

About the BCH About the Cartagena Protocol Supplementary Protocol

Sign in Search records Submit records
Registries: LMO-Organism-Gene Country Profiles
National Report Analyzer

Forums BCH Announcements

Need help?

Knowledge Base FAQs UNEP eLearning Training Site

Contact us at: bch@cbd.int
BCH Biosafety Clearing-House
Subscribe to e-mail notifications
Subscribe to our newsletter